<DOC>
	<DOCNO>NCT02779153</DOCNO>
	<brief_summary>This randomize study explore efficacy , safety steroid spar ability two dos ( 40 U 80 U ) Acthar SLE patient immune mediate hematologic manifestation require steroid use minimum 2 week prior screen .</brief_summary>
	<brief_title>Acthar SLE ( Systemic Lupus Erythematosus )</brief_title>
	<detailed_description>Acthar currently label use exacerbation maintenance therapy select SLE case , however data prospective trial hematologic manifestation SLE available . Due potential effect lower eliminate autoantibody , absence bone marrow suppression , steroid spar effect , Acthar may represent novel therapeutic option recalcitrant case hematologic SLE .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Able provide inform consent . Diagnosis SLE accord American College Rheumatology revise criterion ( fulfil ≥ 4 criterion ) . Hematologic BILAG score due hemolytic anemia thrombocytopenia BILAG A ( include hemolytic anemia hemoglobin &lt; 8.0 g/dL platelet count &lt; 25 x 109 l ) BILAG B ( include hemolytic anemia hemoglobin 8.0 9.9 g/dDL platelet count 25 49 x 109 l ) base screen laboratory assessment . Currently take prednisone ≥ 7.5 mg equivalent hematologic SLE least 2 week prior screen . Use antimalarial NSAIDs ( stable regimen within 4 week prior screen ) , well methotrexate , azathioprine , mycophenolate mofetil ( stable regimen within 4 week prior screen ) permit require . If use , regimen must remain stable study . An increase addition SLE medication time study permit . Ability comply study procedure , include SC injection study medication , adhere concomitant medication restriction , attend schedule office visit . Patients recent history ( &lt; 2 week prior screen ) start prednisone equivalent . Patients active nephritis , define serum creatinine &gt; 2.5 mg/dL protein/creatinine ratio ( PCR ) &gt; 1.5 g/g , patient require hemodialysis within 3 month prior screen . Active central nervous system ( CNS ) lupus ( include seizure , psychosis , organic brain syndrome , cerebrovascular accident , cerebritis , CNS vasculitis ) , require therapeutic intervention within 3 month prior screen . Type 1 type 2 diabetes mellitus ( history gestational diabetes exclusion ) , patient currently take hypoglycemic medication . Patients history concomitant medication use follow : . Receipt follow within 1 month prior screening : . Any steroid injection ( IM , intraarticular , IV ) b . Receipt follow within 3 month prior screen : i. Cyclosporine ii . Any nonbiologic investigational drug c. Receipt follow within 4 month prior screen : i. IVIg ii . Plasmapheresis d. Receipt cyclophosphamide within 6 month prior screen e. Receipt follow within 12 month prior screen : . B cell target therapy ( rituximab antiCD20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alentuzumab ] , belimumab ) ii . Abatacept iii . Any biologic investigational agent Contraindication per Acthar Prescribing Information : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency , adrenal cortical hyperfunction . 1 . For purpose study , osteoporosis define evidence vertebral long bone fracture , lumbar spine Tscore &gt; 2.0 standard deviation mean reference population . 2 . For purpose study , history peptic ulcer define ≤ 6 month prior screen . 3 . For purpose study , congestive heart failure define New York Heart Association Functional Class IIIIV . 4 . For purpose study , uncontrolled hypertension define mean systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg ≥ 3 seated reading take least 5 minute apart screen period . Reproductive status : 1 . Women pregnant , 2 . Women breastfeed , 3 . Women childbearing potential unwilling unable use acceptable method birth control avoid pregnancy entire study period , evaluate Investigator ( woman nonchildbearing potential history hysterectomy , bilateral oophorectomy , postmenopausal history menstrual flow ≥ 12 month prior screen ) . Immune System : Known immunocompromised status ( related SLE therapy SLE ) , include individual undergone organ transplantation know positive human immunodeficiency virus . Patients acute chronic hepatitis C , active hepatitis B infection , positive interferon gamma release assay ( IGRA ) sign symptom concern active tuberculosis ( TB ) ; use antibiotic ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 4 week randomization treatment active infection . Presence clinically significant disease disorder , opinion Investigator ( nature inadequately control ) , might put patient risk due participation study , may influence result study patient 's ability complete study . Any clinically significant laboratory abnormality , base Investigator 's judgment . The following laboratory exclusion apply patient : 1 . AST &gt; 2.5 time upper limit normal ( ULN ) 2 . ALT &gt; 2.5 time ULN 3 . Hemoglobin A1c &gt; 6.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>H.P . Acthar Gel</keyword>
</DOC>